

### Listing of Claims

1. (Currently Amended) A method of treating ~~autoimmune disease~~ a subject that has multiple sclerosis comprising;

administering to [[a]] the subject ~~a with an autoimmune disease that has multiple sclerosis~~ a therapeutically effective combination amount of comprising interferon-beta and a therapeutically effective amount of an antibody that specifically binds the interleukin 2 receptor,

wherein the antibody that specifically binds the interleukin-2 receptor is administered every other week for two weeks and then monthly; once a week; every other week; or once a month,

thereby treating the subject ~~an interleukin 2 receptor antagonist.~~

2. (Canceled).

3. (Currently Amended) The method of claim [[2]] 1, wherein the interferon-beta comprises interferon-beta 1a.

4. (Currently Amended) The method of claim [[2]] 1, wherein the interferon-beta comprises interferon-beta 1b.

5. (Currently Amended) The method of claim [[2]] 1, wherein the interferon-beta comprises a combination of interferon-beta 1a and interferon-beta 1b.

6. (Currently Amended) The method of claim [[2]] 1, wherein the interleukin-2 receptor antagonist is an anti-Tac antibody.

7. (Canceled).

8. (Currently Amended) The method of claim [7] 1, wherein the interferon-beta is administered weekly, ~~and wherein the interleukin-2 receptor antagonist is administered every other week for two weeks and then monthly.~~

9. (Original) The method of claim 8, wherein the interferon-beta is Betaseron and the interleukin-2 receptor antagonist is anti-Tac.

10. (Currently Amended) The method of claim [7] 1, wherein the interferon-beta is administered every other day, ~~and wherein the interleukin-2 receptor antagonist is administered every other week for two weeks and then monthly.~~

11. (Currently Amended)) The method of claim 10, wherein the antibody that specifically binds the interleukin-2 receptor is an ~~the interferon-beta is Avonex or Rebif and the interleukin-2 receptor antagonist is anti-Tac~~ antibody.

12. (Currently Amended) The method of claim [[7]] 1, wherein the interleukin-2 receptor antagonist is daclizumab ~~administered every other week.~~

13. (Currently Amended) The method of claim [[7]] 1, wherein the multiple sclerosis is relapsing-remitting or secondary-progressive.

14. (Currently Amended) The method of claim [[7]] 1, wherein the interferon-beta comprises interferon-beta 1a interferon-beta 1b, or combinations thereof and wherein the interleukin-2 receptor antagonist is anti-Tac.

15. (Canceled).

16. (Original) The method of claim 7, wherein the subject has been treated previously with interferon-beta alone and has failed to respond to treatment with interferon-beta alone.

17. (Currently Amended) The method of claim [[15]] 12, wherein the daclizumab is administered at a dose of 1-2 mg/kg.

18. (Canceled).

19. (Currently Amended) The method of claim [[2]] 1, wherein the interferon-beta is administered subcutaneously.

20. (Currently Amended) A method of treating a subject that has multiple sclerosis comprising

administering to a the subject ~~with that has multiple sclerosis~~ daclizumab at a dose of 1 to 2 mg/kg for every other week for two weeks and then monthly and administering to the subject interferon beta-1b at a dose of 0.006 mg to 2 mg by subcutaneous injection every other day,

wherein the subject ~~who~~ has been previously treated with interferon-beta alone and has failed to respond to treatment with interferon-beta alone, ~~a therapeutically effective dose of anti-Tae.~~

21. (New) A method of treating a subject with multiple sclerosis comprising administering to a the subject with multiple sclerosis daclizumab at a dose of 1 to 2 mg/kg for every other week for two weeks and then monthly and administering to the subject interferon beta-1a intramuscularly at a dose of 15 to 75 ug once a week, wherein the subject has been previously treated with interferon-beta alone and has failed to respond to treatment with interferon-beta alone.

22. (New) The method of claim 1, wherein the antibody that specifically binds the interleukin 2 receptor is administered subcutaneously.

23. (New) The method of claim 22, wherein the antibody that specifically binds the interleukin 2 receptor is administered every other week or every month.

24. (New) The method of claim 1, wherein the antibody that specifically binds the interleukin 2 receptor is administered at a dose of 1 mg/kg or 2mg/kg.

25. (New) The method of claim 22, wherein the antibody that specifically binds the interleukin 2 receptor is administered at a dose of 1 mg/kg or 2mg/kg.

26. (New) The method of claim 1, wherein the antibody that specifically binds the interleukin 2 receptor is administered every other week for two weeks and then monthly.